This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lin, Y.-C. Articles by Chen, C.-C. Search for Related Content PubMed PubMed Citation Articles by Lin, Y.-C. Articles by Chen, C.-C.

Statins Increase p21 through Inhibition of Histone Deacetylase Activity and Release of Promoter-Associated HDAC1/2

¹ Department of Pharmacology and ² School of Pharmacy, College of Medicine, National Taiwan University; ³ Division of Mechanics, Research Center for Applied Sciences and ⁴ Institute of Biomedical Science, Academia Sinica, Taipei, Taiwan

Requests for reprints: Ching-Chow Chen, Department of Pharmacology, College of Medicine, National Taiwan University, No. 1, Jen-Ai Road, Section 1, Taipei 10018, Taiwan. Phone: 886-2-23123456, ext. 8321; Fax: 886-2-23947833; E-mail: chingchowchen{at}ntu.edu.tw.

Key Words: HDAC • HMG-CoA reductase inhibitors • p21 • statins

Statins are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors broadly used for the control of hypercholesterolemia. Recently, they are reported to have beneficial effects on certain cancers. In this study, we show that statins inhibited the histone deacetylase (HDAC) activity and increased the accumulation of acetylated histone-H3 and the expression of p21^WAF/CIP in human cancer cells. Computational modeling showed the direct interaction of the carboxylic acid moiety of statins with the catalytic site of HDAC2. In the subsequent enzymatic assay, it was shown that lovastatin inhibited HDAC2 activity competitively with a K_i value of 31.6 µmol/L. Sp1 but not p53 sites were found to be the statins-responsive element shown by p21 luciferase-promoter assays. DNA affinity protein binding assay and chromatin immunoprecipitation assay showed the dissociation of HDAC1/2 and association of CBP, leading to the histone-H3 acetylation on the Sp1 sites of p21 promoter. In vitro cell proliferation and in vivo tumor growth were both inhibited by statins. These results suggest a novel mechanism for statins through abrogation of the HDAC activity and promoter histone-H3 acetylation to regulate p21 expression. Therefore, statins might serve as novel HDAC inhibitors for cancer therapy and chemoprevention. [Cancer Res 2008;68(7):2375–83]

This article has been cited by other articles:

				A. A. Zeki, L. Franzi, J. Last, and N. J. Kenyon Simvastatin Inhibits Airway Hyperreactivity: Implications for the Mevalonate Pathway and Beyond Am. J. Respir. Crit. Care Med., October 15, 2009; 180(8): 731 - 740. [Abstract] [Full Text] [PDF]

				L. Escoubet-Lozach, I-L. Lin, K. Jensen-Pergakes, H. A. Brady, A. K. Gandhi, P. H. Schafer, G. W. Muller, P. J. Worland, K. W.H. Chan, and D. Verhelle Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism Cancer Res., September 15, 2009; 69(18): 7347 - 7356. [Abstract] [Full Text] [PDF]

				D. Pons, F. R. de Vries, P. J. van den Elsen, B. T. Heijmans, P. H.A. Quax, and J. W. Jukema Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease Eur. Heart J., February 1, 2009; 30(3): 266 - 277. [Abstract] [Full Text] [PDF]